Loci Orthopaedics

Executive Summary

Loci Orthopaedics is a privately held medical device company based in Galway, Ireland, developing innovative solutions for unmet clinical needs in the extremities orthopaedics market. The company's lead product is a novel implant for the treatment of thumb base arthritis (CMC arthritis), a condition affecting millions globally with limited surgical options. Loci's implant is designed to preserve bone stock and restore natural joint mechanics, potentially offering advantages over existing arthroplasty and fusion procedures. Founded in 2015, the company operates at the intersection of medical devices and regenerative medicine, and has been recognized with multiple awards for its innovation. While Loci has not disclosed significant funding rounds or revenue, its focused pipeline and proprietary technology position it as a potential disruptor in the hand and wrist arthroplasty space. The company is likely in late preclinical or early clinical stages, with the next milestones revolving around regulatory clearance and clinical validation. Given the large addressable market and lack of effective long-term solutions for thumb arthritis, Loci's platform could capture meaningful market share if clinical outcomes prove superior. However, as a private, early-stage entity, execution risk remains elevated, and limited public information constrains visibility. The company's valuation is not disclosed, and its stage is not explicitly stated, but based on typical medtech trajectories, it may be seeking Series A or B funding to support pivotal trials. Overall, Loci Orthopaedics presents a compelling niche opportunity within orthopaedics, with the potential for significant value creation if technical and regulatory hurdles are overcome.

Upcoming Catalysts (preview)

• Q4 2026CE Mark approval for thumb base arthritis implant60% success
• H2 2026First-in-human clinical trial results70% success
• Q3 2026Strategic partnership or licensing deal for distribution50% success